Covid-19 roundup: CEPI pours $328M in­to Clover's vac­cine; For­mer Shkre­li com­pa­ny li­cens­es po­ten­tial treat­ment for $20M

Af­ter pour­ing $69.5 mil­lion in­to the de­vel­op­ment Clover Bio­phar­ma­ceu­ti­cals’ Covid-19 vac­cine, CEPI is back with an­oth­er $250 mil­lion-plus to fin­ish what it start­ed.

The lat­est fund­ing will bring CEPI’s to­tal con­tri­bu­tion to $328 mil­lion, pro­pelling Clover’s pro­tein-based S-Trimer vac­cine can­di­date in­to a piv­otal Phase II/III ef­fi­ca­cy tri­al. Clover is lag­ging be­hind fron­trun­ners like Mod­er­na and Pfiz­er, which both be­gan Phase III tri­als in Ju­ly and said they could have the safe­ty da­ta nec­es­sary to ap­ply for an EUA this month. Clover ex­pects to be­gin its own Phase II/III tri­al this year, and is shoot­ing for po­ten­tial li­cen­sure in 2021.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER